Critical Care Therapeutics Market Size, Share, Trends, Analysis and Forecasts To 2021
Market Research analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62 % during the period 2017-2021.
The following companies as the key players in the global critical care therapeutics market: CSL Behring, Grifols, Kedrion Biopharma, Octapharma, and Shire.
Other Prominent Vendors in the market are: Abeona Therapeutics, ADMA Biologics, Albumedix, Armetheon, Asklepios BioPharmaceutical, Aspen Pharma, Baxter, Bayer HealthCare, Bio Products Laboratory, BioDelivery Sciences, Biogen Idec, BioMarin, Biotest Pharmaceuticals, Bristol-Myers Squibb, Catalyst Biosciences, China Biologic Products, Cosmo Pharmaceuticals, Kamada, King Pharmaceuticals, Medxbio, Merck, Mitsubishi Tanabe Pharma, Novo Nordisk, Novozymes, Portola Pharmaceuticals, ProMetic Life Sciences, rEVO Biologics, Rockwell Medical, Sanquin, Shanghai RAAS, Teva Pharmaceutical, The Medicines Company, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, and Ventria Bioscience.
Download Sample Report @ https:// marketreportscenter. com / request-sample / 500950
Commenting on the report, an analyst from Technavio’ s team said:“ One trend in market is establishment of plasma fractionation facilities in emerging economies by global players. Plasma fractionation in developed countries is proving very costly, so there has been a growing focus of vendors to tap the emerging economies such as the Middle East, Africa, China, and India. These geographies become a favorite due to the easy availability of skilled personnel, raw materials, cheap labor and land, a larger volume of available plasma due to large population base, and supportive government regulations. However, currently the presence of plasma fractionation facilities is very much limited to China within emerging countries, but in future, the incentives listed above should be driving the vendors to establish more facilities in these regions. For instance, in 2010, Celestial Biologicals, an associate company of Intas Biopharmaceuticals, in collaboration with GE Healthcare started a plasma fractionation facility in India. Going forward, to benefit from the unmet demand in the emerging markets and the incentives of opening such facilities in the region, would drive global players to open number of such facilities in the region.
According to the report, one driver in market is increasing surgical procedures. The increasing surgical procedures such as hip and knee replacements will increase the risk of DVT, thereby driving the market growth. Surgeries often result in long periods of immobility, thus increasing the chances of developing DVT due to reduced blood flow. It is reported that over a million Americans undergo joint replacement surgeries every year. Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT. For instance, according to the CDC 2015 report, around 719,000 knee replacement surgeries and 332,000 hip replacement surgeries are performed in the US every year.